U.S. Patent Office Allows New CEL-SCI Patent For LEAPS Vaccine Platform Technology
January 30 2018 - 10:00AM
Business Wire
New LEAPS Patent aimed at Influenza and
other Infectious Diseases
CEL-SCI Corporation (NYSE American: CVM) today announced
the U.S. Patent and Trademark Office has allowed a patent titled,
“Method for Inducing an Immune Response and Formulations Thereof”
for the Company’s LEAPS technology. CEL-SCI’s patented invention
relates to methods for diagnosing, preventing, and treating disease
by generating or modulating the immune response through the use of
specific peptides.
This specific allowed patent expands the LEAPS platform
technology protection by addressing the invention’s methods for
diagnosing, preventing and treating infectious diseases, including
using cellular delivery approaches, with indications such as
influenza, including swine and avian flu, other viruses such as
herpes, and also bacteria and parasites.
The LEAPS platform technology is currently being developed as a
therapeutic vaccine for rheumatoid arthritis (RA) under a $1.5
million grant from the U.S. National Institutes of Health (NIH).
Upon completion of preclinical and Investigational New Drug (IND)
enabling studies for the LEAPS-based rheumatoid arthritis vaccine
candidate CEL-4000, CEL-SCI intends to file an IND application with
the U.S. Food and Drug Administration.
“As we move the first LEAPS platform vaccine candidate towards
potential human studies, we are pleased by this important extra
step forward. This patent expands and fortifies the intellectual
property protection for our LEAPS technology platform,” said Dr.
Daniel Zimmerman, Senior Vice President of Research, Cellular
Immunology.
LEAPS is a patented, T-cell modulation, peptide epitope delivery
technology that enables CEL-SCI to design and synthesize
proprietary peptide immunogens. LEAPS compounds consist of a small
T-cell binding peptide ligand linked with a disease-associated
peptide antigen.
This platform technology has been shown in several animal models
to preferentially direct the immune response to a cellular (e.g.
T-cell), humoral (antibody) or mixed pathway and has been shown to
involve upregulation of T-regulatory (Treg) cells in some animal
models. It has the potential to be utilized in diseases for which
antigenic epitope sequences have already been identified, such as:
a number of infectious diseases, some cancers, autoimmune diseases
(e.g., RA), allergic asthma and allergy, and select CNS diseases
(e.g., Alzheimer's).
About CEL-SCI Corporation
CEL-SCI is a Phase 3 cancer immunotherapy company. When it comes
to cancer immunotherapy, CEL-SCI believes it is most logical to
boost the patient’s immune system while it is still intact in order
to have the greatest possible impact on survival. Therefore,
CEL-SCI treats patients who are newly diagnosed with head and neck
cancer with its lead investigational immunotherapy Multikine*
(Leukocyte Interleukin, Injection), BEFORE they have received
surgery, radiation and/or chemotherapy. This approach is unique.
Most other cancer immunotherapies are used only after conventional
therapies have been tried and/or failed. Head and neck cancer
represents about 6% of all cancers. Multikine has received Orphan
Drug designation from the FDA for the treatment of head and neck
cancer patients with advanced squamous cell carcinoma.
The Company’s LEAPS technology is being developed as a
therapeutic vaccine for rheumatoid arthritis and is supported by
grants from the National Institutes of Health. The Company has
operations in Vienna, Virginia, and in/near Baltimore,
Maryland.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. When used in this press release, the words "intends,"
"believes," "anticipated," "plans" and "expects," and similar
expressions, are intended to identify forward-looking statements.
Such statements are subject to risks and uncertainties that could
cause actual results to differ materially from those projected.
Factors that could cause or contribute to such differences include,
an inability to duplicate the clinical results demonstrated in
clinical studies, timely development of any potential products that
can be shown to be safe and effective, receiving necessary
regulatory approvals, difficulties in manufacturing any of the
Company's potential products, inability to raise the necessary
capital and the risk factors set forth from time to time in
CEL-SCI’s filings with the Securities and Exchange Commission,
including but not limited to its report on Form 10-K for the year
ended September 30, 2017. The Company undertakes no obligation to
publicly release the result of any revision to these
forward-looking statements which may be made to reflect the events
or circumstances after the date hereof or to reflect the occurrence
of unanticipated events.
* Multikine (Leukocyte Interleukin, Injection) is the trademark
that CEL-SCI has registered for this investigational therapy, and
this proprietary name is subject to FDA review in connection with
the Company's future anticipated regulatory submission for
approval. Multikine has not been licensed or approved for sale,
barter or exchange by the FDA or any other regulatory agency.
Similarly, its safety or efficacy has not been established for any
use. Moreover, no definitive conclusions can be drawn from the
early-phase, clinical-trials data involving the investigational
therapy Multikine. Further research is required, and early-phase
clinical trial results must be confirmed in the Phase 3 clinical
trial of this investigational therapy that is in progress.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180130005803/en/
COMPANY CONTACT:CEL-SCI CorporationGavin de Windt,
703-506-9460
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Apr 2024 to May 2024
Cel Sci (AMEX:CVM)
Historical Stock Chart
From May 2023 to May 2024